Logo image of ALMDT.PA

MEDIAN TECHNOLOGIES (ALMDT.PA) Stock Fundamental Analysis

EPA:ALMDT - Euronext Paris - Matif - FR0011049824 - Common Stock - Currency: EUR

3.35  -0.72 (-17.69%)

Fundamental Rating

2

Taking everything into account, ALMDT scores 2 out of 10 in our fundamental rating. ALMDT was compared to 12 industry peers in the Health Care Technology industry. Both the profitability and financial health of ALMDT have multiple concerns. ALMDT is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

In the past year ALMDT has reported negative net income.
ALMDT had a negative operating cash flow in the past year.
ALMDT had negative earnings in each of the past 5 years.
In the past 5 years ALMDT always reported negative operating cash flow.
ALMDT.PA Yearly Net Income VS EBIT VS OCF VS FCFALMDT.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5M -10M -15M -20M

1.2 Ratios

ALMDT's Return On Assets of -77.03% is on the low side compared to the rest of the industry. ALMDT is outperformed by 90.91% of its industry peers.
Industry RankSector Rank
ROA -77.03%
ROE N/A
ROIC N/A
ROA(3y)-53.73%
ROA(5y)-52.27%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALMDT.PA Yearly ROA, ROE, ROICALMDT.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200 -400 -600

1.3 Margins

ALMDT's Gross Margin of 105.00% is amongst the best of the industry. ALMDT outperforms 100.00% of its industry peers.
ALMDT's Gross Margin has been stable in the last couple of years.
ALMDT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 105%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.82%
GM growth 5Y1.31%
ALMDT.PA Yearly Profit, Operating, Gross MarginsALMDT.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100 -100 -200

0

2. Health

2.1 Basic Checks

ALMDT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ALMDT has been increased compared to 1 year ago.
ALMDT has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ALMDT has a worse debt to assets ratio.
ALMDT.PA Yearly Shares OutstandingALMDT.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M
ALMDT.PA Yearly Total Debt VS Total AssetsALMDT.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -6.77, we must say that ALMDT is in the distress zone and has some risk of bankruptcy.
ALMDT has a Altman-Z score of -6.77. This is amonst the worse of the industry: ALMDT underperforms 81.82% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -6.77
ROIC/WACCN/A
WACC6.75%
ALMDT.PA Yearly LT Debt VS Equity VS FCFALMDT.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M

2.3 Liquidity

A Current Ratio of 0.69 indicates that ALMDT may have some problems paying its short term obligations.
With a Current ratio value of 0.69, ALMDT is not doing good in the industry: 90.91% of the companies in the same industry are doing better.
A Quick Ratio of 0.69 indicates that ALMDT may have some problems paying its short term obligations.
ALMDT has a Quick ratio of 0.69. This is amonst the worse of the industry: ALMDT underperforms 90.91% of its industry peers.
Industry RankSector Rank
Current Ratio 0.69
Quick Ratio 0.69
ALMDT.PA Yearly Current Assets VS Current LiabilitesALMDT.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

5

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 3.87% over the past year.
The Revenue has decreased by -1.96% in the past year.
ALMDT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 28.52% yearly.
EPS 1Y (TTM)3.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5.95%
Revenue 1Y (TTM)-1.96%
Revenue growth 3Y18.14%
Revenue growth 5Y28.52%
Sales Q2Q%-3.45%

3.2 Future

Based on estimates for the next years, ALMDT will show a very strong growth in Earnings Per Share. The EPS will grow by 24.16% on average per year.
Based on estimates for the next years, ALMDT will show a quite strong growth in Revenue. The Revenue will grow by 14.15% on average per year.
EPS Next Y13.62%
EPS Next 2Y10.23%
EPS Next 3Y24.16%
EPS Next 5YN/A
Revenue Next Year-5.29%
Revenue Next 2Y5.8%
Revenue Next 3Y14.15%
Revenue Next 5YN/A

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ALMDT.PA Yearly Revenue VS EstimatesALMDT.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 10M 20M 30M
ALMDT.PA Yearly EPS VS EstimatesALMDT.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -0.5 -1

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALMDT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALMDT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALMDT.PA Price Earnings VS Forward Price EarningsALMDT.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALMDT.PA Per share dataALMDT.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as ALMDT's earnings are expected to grow with 24.16% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.23%
EPS Next 3Y24.16%

0

5. Dividend

5.1 Amount

No dividends for ALMDT!.
Industry RankSector Rank
Dividend Yield N/A

MEDIAN TECHNOLOGIES

EPA:ALMDT (2/4/2025, 7:00:00 PM)

3.35

-0.72 (-17.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)10-24 2024-10-24
Earnings (Next)N/A N/A
Inst Owners19.81%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap61.94M
Analysts85.45
Price Target16.97 (406.57%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)2.82%
EPS NY rev (3m)8.71%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)4.99%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.84
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.29
EYN/A
EPS(NY)-1.13
Fwd EYN/A
FCF(TTM)-1.1
FCFYN/A
OCF(TTM)-1.03
OCFYN/A
SpS1.18
BVpS-1.18
TBVpS-1.3
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -77.03%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 105%
FCFM N/A
ROA(3y)-53.73%
ROA(5y)-52.27%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.82%
GM growth 5Y1.31%
F-Score3
Asset Turnover0.66
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 70.23%
Cap/Sales 6.22%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.69
Quick Ratio 0.69
Altman-Z -6.77
F-Score3
WACC6.75%
ROIC/WACCN/A
Cap/Depr(3y)107.7%
Cap/Depr(5y)N/A
Cap/Sales(3y)4.67%
Cap/Sales(5y)3.73%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5.95%
EPS Next Y13.62%
EPS Next 2Y10.23%
EPS Next 3Y24.16%
EPS Next 5YN/A
Revenue 1Y (TTM)-1.96%
Revenue growth 3Y18.14%
Revenue growth 5Y28.52%
Sales Q2Q%-3.45%
Revenue Next Year-5.29%
Revenue Next 2Y5.8%
Revenue Next 3Y14.15%
Revenue Next 5YN/A
EBIT growth 1Y-7.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year10.31%
EBIT Next 3Y15.38%
EBIT Next 5YN/A
FCF growth 1Y-39.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-38.62%
OCF growth 3YN/A
OCF growth 5YN/A